Skip to main content
. 2017 Oct;8(3):e148–e156. doi: 10.2500/ar.2017.8.0216

Figure 4.

Figure 4.

The proportion of patients treated with MP-AzeFlu (Dymista®) who had well-controlled (i.e., a visual analog scale [VAS] score of ≤38 mm), partly controlled (i.e., VAS score of ≤55 mm), and uncontrolled allergic rhinitis over time. Data are presented as Kaplan Meier estimates for days 1, 3, 7, and 14, and are interpolated for the other days.